Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Extracellular vesicles can cross the blood–brain barrier (BBB), but little is known about passage. Here, we used multiple-time regression analysis to examine the ability of 10 exosome populations derived from mouse, human, cancerous, and non-cancerous cell lines to cross the BBB. All crossed the BBB, but rates varied over 10-fold. Lipopolysaccharide (LPS), an activator of the innate immune system, enhanced uptake independently of BBB disruption for six exosomes and decreased uptake for one. Wheatgerm agglutinin (WGA) modulated transport of five exosome populations, suggesting passage by adsorptive transcytosis. Mannose 6-phosphate inhibited uptake of J774A.1, demonstrating that its BBB transporter is the mannose 6-phosphate receptor. Uptake rates, patterns, and effects of LPS or WGA were not predicted by exosome source (mouse vs. human) or cancer status of the cell lines. The cell surface proteins CD46, AVβ6, AVβ3, and ICAM-1 were variably expressed but not predictive of transport rate nor responses to LPS or WGA. A brain-to-blood efflux mechanism variably affected CNS retention and explains how CNS-derived exosomes enter blood. In summary, all exosomes tested here readily crossed the BBB, but at varying rates and by a variety of vesicular-mediated mechanisms involving specific transporters, adsorptive transcytosis, and a brain-to-blood efflux system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 On-bead flow cytometry of exosome populations isolated from supernatants of 4 different cell lines, captured on streptavidin beads coated with biotinylated anti-CD63 mAbs and stained with the labeled detection Abs specific for CD46, αVβ6, αVβ3 and ICAM1 as described in Methods. Data are relative fluorescence intensity (RFI) values calculated as mean fluorescence intensity (MFI) of an experimental sample/MFI of an isotype control Ab. [White peaks = experimental samples; hatched peaks = isotope controls]. Note that exosomes produced by non-malignant cells (HaCaT and primary T cells) appear to differ from exosomes produced by malignant cells by the absence of αVβ3 and lower expression levels of αVβ6. Representative results are from 1 to 3 detection experiments performed with each exosome population.](https://figures.cochat.ai/paper-figures/624d7ee716904379955ce30fbf39b5dc/transport-of-extracellular-vesicles-across-the-blood-brain-barrier-brain-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, EVs have inherent targeting capabilities and can cross the BBB, facilitating efficient delivery of therapeutic cargo to the CNS [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Brain-derived EVs have been found to harbor the ability to penetrate the BBB. This breakdown is crucial as it potentially allows for releasing these EVs into peripheral circulation [54–57].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“sEVs can cross the blood–brain barrier and deliver cargo with crucial roles in many neurological disorders [17–23].”
From Differential RNA packaging into small extracellular vesicles by neurons and astrocytes (2021) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · cited 3×
“EVs we refer to as “exosomes” were isolated by mini-size exclusion chromatography (SEC) from supernatants of 10 different human or murine cell lines (Table 1) and characterized according to the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) criteria [2], as is routinely done in our laborato…”
BackgroundMethodShedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369 · cited 2×
“of parent cells, where they are formed by inverse membrane invagination as intraluminal vesicles inside multivesicular bodies (MVBs) [4].”
BackgroundExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Exosomes are a subset of small extracellular vesicles (EVs) that are produced by all normal and malignant cells and are present in all body fluids [1].”
BackgroundGraphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Exosomes as drug delivery vehicles for Parkinson’s disease therapy
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., Patel, T., Piroyan, A., Sokolsky, M., Kabanov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.033 · Cited by 2,009 · cited 1×
“, drug-loaded exosomes enter the brain using the same mechanisms as those employed by the parent cells [12].”
BackgroundAbels, E. R., & Breakefield, X. O. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0366-z · Cited by 1,678 · cited 1×
“Among the various EVs, exosomes are sized at 30–150 nm in diameter and are of special interest because of their origin, their ability to freely circulate and infiltrate various tissues and their molecular content mirroring that of parental cells [3].”
BackgroundZhang, H., Freitas, D., Kim, H. S., Fabijanic, K., Li, Z., Chen, H., Mark, M. T., Molina, H., Martin, A. B., Bojmar, L., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0040-4 · Cited by 1,613 · cited 1×
“The orientation of surface proteins in exosome membranes resembles that in the cell membrane of parent cells [5].”
BackgroundExtracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,429 · cited 2×
“Exosomes serve as an intercellular communication system, shuttling messages between cells and also conveying peptides, proteins, and genetic materials from parental to recipient cells [6].”
BackgroundFrom blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery
Banks, W. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.21 · Cited by 1,204
Self-citationPlasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citation
Research works printed but not linked: 1
- Nicolini, M., and Zatta, P.F. (1994). Glycoconjugates and anionic sites in the blood-brain barrier. Glycobiology and the Brain, Pergamon Press.
Cited by
Items 101–200 of 569
Zheng, X., Xing, Y., Sun, K., Jin, H., Zhao, W. G., & Yu, F. D. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301325 · Cited by 45
The crosstalk between brain and periphery: Implications for brain health and disease
Gonçalves, R. A., & Felice, F. G. D. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108728 · Cited by 48
Yom-Tov, N., Guy, R., & Offen, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114535 · Cited by 42
The emerging role of exosomes in communication between the periphery and the central nervous system
Han, W., Zhang, H., Feng, L., Dang, R., Wang, J., Cui, C., & Jiang, P. (2023) · MedComm · doi:10.1002/mco2.410 · Cited by 48
“17,18 Exosomes originating from the periphery can be transported to the brain, and exosomes from the brain can also be located in the periphery.”
BackgroundBidirectional Communication Between the Brain and Other Organs: The Role of Extracellular Vesicles
Zhou, W., Zhao, L., Mao, Z., Wang, Z., Zhang, Z., & Li, M. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01345-5 · Cited by 46
“Chavez et al. (Chavez et al. 2021) reported that circulating blood exosomes containing caspase-1 crossed the BBB and caused neuroinflammation and caspase-1/gasdermin D activation in neonatal rats with ventilation-induced lung injury (VILI); this interaction could lead to brain damage and neurodevelopmental deficits in…”
BackgroundInfluentialMacedo-Pereira, A., Martins, C., Lima, J., & Sarmento, B. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.038 · Cited by 38
The status of extracellular vesicles as drug carriers and therapeutics
Chaudhari, A. P., Budayr, O. M., Bonacquisti, E. E., Kussatz, C. C., Bannon, M. S., Law, K. J., Liu, Y., Bolton, M. L., Glassman, P. M., Huang, L., et al. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00405-x · Cited by 63
Bang, O. Y., & Kim, J.-E. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.1.162 · Cited by 42
Morales-Prieto, D. M., Murrieta-Coxca, J. M., Stojiljkovic, M., Diezel, C., Streicher, P. E., Henao-Restrepo, J. A., Röstel, F., Lindner, J., Witte, O. W., Weis, S., et al. (2022) · Cells · doi:10.3390/cells11040625 · Cited by 38
“It is known that clearance rates (t1/2) for sEVs from the blood are in the range of a few minutes [15].”
BackgroundResultInfluentialRan, L., Kong, Y., Xiang, J.-J., Zeng, Q., Zhang, C., Shi, L., Qiu, H., Liu, C., Wu, L.-L., Li, Y., et al. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7110 · Cited by 46
“Although EV pellets are able to cross the blood-brain barrier [78], the fraction of neuron-derived EVs in EV pellets from the peripheral blood remains unknown, and further studies are required to verify that molecules present in the peripheral blood represent CNS abnormalities.”
BackgroundSpecial delEVery: Extracellular Vesicles as Promising Delivery Platform to the Brain
Pauwels, M. J., Vandendriessche, C., & Vandenbroucke, R. E. (2021) · Biomedicines · doi:10.3390/biomedicines9111734 · Cited by 39
“Moreover, some specific transport mechanisms including clathrin-dependent endocytosis [62,66], and caveolin dependent routes [62], RMT [63,65,67] and adsorptive transcytosis [65] have been identified (see Section 3.3.1, Table 1).”
BackgroundResultInfluentialEffects of glioblastoma-derived extracellular vesicles on the functions of immune cells
Musatova, O. E., & Rubtsov, Y. P. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1060000 · Cited by 42
“However, EVs can cross the blood-brain barrier presumably using transcytosis (Banks et al., 2020; Ridder et al., 2014), so EVs could be found in biological fluids.”
BackgroundWang, X., Yang, H., Liu, C., & Liu, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1194210 · Cited by 36
“What’s more, because of their intercellular communication abilities and the capacity to cross the blood–brain barrier (BBB) (Banks et al., 2020; Morales-Prieto et al., 2022), EVs have emerged as potential tools for breakthroughs in the clinical diagnosis of brain disorders.”
Yadav, K., Vijayalakshmi, R., Sahu, K. K., Sure, P., Chahal, K., Yadav, R. K., Sucheta, Dubey, A., Jha, M., & Pradhan, M. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114298 · Cited by 41
Badhwar, A., Hirschberg, Y., Valle‐Tamayo, N., Iulita, M. F., Udeh‐Momoh, C. T., Matton, A., Tarawneh, R. M., Rissman, R. A., Ledreux, A., Winston, C. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13823 · Cited by 38
“18 Their ability to diffuse from CNS to blood, from where they can be isolated, make them an attractive resource for novel biomarker discovery and mechanistic insights into brain disease.”
Dogan, A. B., Marsh, S. R., Tschetter, R. J., Beard, C. E., Amin, M. R., Jourdan, L. J., & Gourdie, R. G. (2025) · Journal of Biological Engineering · doi:10.1186/s13036-024-00470-z · Cited by 47
“This interaction might also play a role in mEV during mEV trans-cytosis [75, 76].”
Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment
Chen, T., Chen, D., Su, W., Liang, J., Liu, X., & Cai, M. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1600227 · Cited by 61
Gao, L., Wang, H., Tian, C., & Zucker, I. H. (2021) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000257 · Cited by 40
Alharbi, W. S., Hareeri, R. H., Bazuhair, M. A., Alfaleh, M. A., Alhakamy, N. A., Fahmy, U. A., Alamoudi, A. A., Badr-Eldin, S. M., Ahmed, O. A. A., AlGhamdi, S. A., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122627 · Cited by 36
“These parameters included the FLB maximum plasma concentration (Cmax), its corresponding time (Tmax), the area under the curve from zero to the last sampling point (AUC0–24), and the area under the curve from zero to infinity (AUC0–∞) in both plasma [4] and brain samples [25].”
MethodPhysiological and pathological consequences of exosomes at the blood–brain-barrier interface
Salimi, L., Seyedaghamiri, F., Karimipour, M., Mobarak, H., Mardi, N., Narmi, M. T., & Rahbarghazi, R. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01142-z · Cited by 37
“Upon the attachment of Exo ligands to cognate receptors, clathrin vesicles containing both receptors and ligands are generated and can deliver their contents at the abluminal surface [66].”
BackgroundLyophilization Based Isolation of Exosomes
Qazi, R., Sajid, Z., Zhao, C., Hussain, I., Iftikhar, F., Jameel, M., Rehman, F. U., & Mian, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310477 · Cited by 41
“The exosomes also benefit from a natural ability to traverse all physiological barriers in the body, and, pertinently, the blood–brain barrier (BBB), which presents a significant obstacle in the amelioration of brain disease or resection of brain cancers [12].”
BackgroundExtracellular vesicles in pharmacology: Novel approaches in diagnostics and therapy
Quadri, Z., Elsherbini, A. M., & Bieberich, E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105980 · Cited by 40
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33
“A recent investigative delineated the trans-BBB trafficking of various EV populations, discerning a spectrum of permeability across mouse, human, neoplastic, and non-neoplastic cellular lineages, thereby illuminating the differential crossing efficacies that could be harnessed therapeutically [131].”
BackgroundApplications of Stem Cell-Derived Extracellular Vesicles in Nerve Regeneration
Yavuz, B., Mutlu, E. C., Ahmed, Z., Ben‐Nissan, B., & Stamboulis, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115863 · Cited by 34
“Stem cell-derived EVs can spread therapeutic properties locally and systemically, making them a safer alternative to cellular therapy and transplantation surgery.”
BackgroundShi, X., Zhang, L., Wu, S., Zhang, C., Mamtilahun, M., Li, Y.-F., Zhang, Z., Zuo, C., Cui, F., Li, W., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70031 · Cited by 34
“In addition, directly conjugating EVs with imaging tracers such as 125 I via physical absorption is very straightforward (Banks et al., 2020), but the labelling is unstable, and easily detaches from EVs under physiological conditions.”
Extracellular Vesicles Taken up by Astrocytes
Ogaki, A., Ikegaya, Y., & Koyama, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910553 · Cited by 36
“The route that EVs take during this transition remains unresolved, but a BBB- or BCSFB-mediated route has been suggested [64,65].”
BackgroundExosomes: Biological Pharmaceutical Nanovectors for Theranostics
Thomas, S. C., Kim, J.-W., Pauletti, G. M., Hassett, D. J., & Kotagiri, N. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.808614 · Cited by 42
“Glycoproteins such as the wheatgerm agglutinin, innate immune status activation, BBB inflammation and receptorligand interactions such as with mannose-6-phosphate were found to modulate the penetration mechanism, however the effect of these factors were again found to be highly variable (Banks et al., 2020).”
BackgroundEngineered anti-EGFRvIII targeted exosomes induce apoptosis in glioblastoma multiforme
Rahmani, R., Kiani, J., Tong, W. Y., Soleimani, M., Voelcker, N. H., & Arefian, E. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2152819 · Cited by 37
Bhattacharyya, P., Biswas, A., & Biswas, S. C. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1037903 · Cited by 39
“Further, exosomes are specifically important in context to brain diseases as they are known to cross the blood-brainbarrier effectively (Haney et al., 2015; Banks et al., 2020), thereby allowing the brain-derived miRNAs to come into the circulation.”
BackgroundDeciphering psychobiotics’ mechanism of action: bacterial extracellular vesicles in the spotlight
Bleibel, L., Dziomba, S., Waleron, K., Kowalczyk, E., & Karbownik, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1211447 · Cited by 37
Delivery of mitochondria-containing extracellular vesicles to the BBB for ischemic stroke therapy
Dave, K. M., Stolz, D. B., & Manickam, D. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2279115 · Cited by 37
“CD46, ICAM1, and integrin proteins on the EXO membranes facilitate their transport to the BBB via adsorptive transcytosis [105].”
BackgroundInfluentialDifferential RNA packaging into small extracellular vesicles by neurons and astrocytes
Luo, X., Jean-Toussaint, R., Sacan, A., & Ajit, S. K. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00757-4 · Cited by 32
Cell-specific extracellular vesicle-encapsulated exogenous GABA controls seizures in epilepsy
Abhijna Ballal, R., Shivakumar Reddy, K., Chandran, D., Hegde, S., Upadhya, R., Kumar, P., Shenoy, S., Devi, V., & Upadhya, D. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03721-4 · Cited by 34
“EVs are considered next-generation drug delivery systems as they can cross BBBs and reach neurons and glial cells [27, 28, 41].”
BackgroundJindal, A., Mainuddin, Kumar, A., Ratnesh, R. K., & Singh, J. (2024) · Indian Journal of Microbiology · doi:10.1007/s12088-024-01330-6 · Cited by 38
“Exosomes were examined from 10 cell lines (cancerous and normal) and it was shown that mostly all of them could partially penetrate the blood–brain barrier, there were tenfold differences in how much of them were absorbed into the brain [83–85].”
The Glycocalyx: The Importance of Sugar Coating the Blood-Brain Barrier
Dancy, C., Heintzelman, K. E., & Katt, M. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158404 · Cited by 37
“This enhancement bolstered the targeting potential of the anti-GD2 mAb, exemplifying the possibility that strategic modifications to the GCX can be used to optimize therapeutic outcomes.”
BackgroundReprogramming Extracellular Vesicles for Protein Therapeutics Delivery
Ovchinnikova, L. A., Terekhov, S. S., Ziganshin, R., Bagrov, D. V., Filimonova, I. N., Zalevsky, A. O., & Lomakin, Y. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060768 · Cited by 34
“The major advantages of EVs as therapeutic carriers encompass: (i) natural biocompatibility as their envelope is formed from the same cell membrane [19,20], (ii) the ability to pass through the blood–brain barrier [21,22] and (iii) their versatility as a therapeutic tool since surface receptors could be easily modifie…”
BackgroundHirsch, Y., Geraghty, J. R., Reiter, C. R., Katz, E. A., Little, C. F., Tobin, M. K., & Testai, F. D. (2022) · Translational Stroke Research · doi:10.1007/s12975-022-01027-2 · Cited by 34
“(2020) examined the kinetics of ten different EV populations from both mice and human plasma crossing the BBB in vivo and found that while all EV populations studied were able to cross the BBB, they did so at various rates and through different mechanisms [49].”
BackgroundExtracellular vesicles and lipoproteins – Smart messengers of blood cells in the circulation
Nguyen, P. H. D., Le, A. H., Pek, J. S. Q., Pham, T. T., Jayasinghe, M. K., Do, D. V., Phung, C. D., & Le, M. T. N. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.49 · Cited by 31
“Notably, BCEVs possess an endogenous capability to permeate into tissues and cross cellular barriers, including the blood-brain barrier (BBB) in some instances (Banks et al., 2020; Saint-Pol et al., 2020), which makes them a potentially safe and efficient means to target brain diseases.”
BackgroundExosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy
Yang, S., Sun, Y., Liu, W., Zhang, Y., Sun, G., Xiang, B., & Yang, J. (2024) · Cancers · doi:10.3390/cancers16040823 · Cited by 37
“Banks and colleagues investigated the capacity of 10 exosome populations obtained from mouse, human, cancerous, and non-cancerous cell lines to traverse the blood– brain barrier [41].”
BackgroundSun, M., Qin, F., Bu, Q., Zhao, Y., Yang, X., Zhang, D., & Cen, X. (2025) · MedComm · doi:10.1002/mco2.70386 · Cited by 47
“These include the low-density lipoprotein receptor, insulin receptor, G-protein-coupled receptors (GPCRs), and receptor for advanced glycation end-products (RAGE) [285].”
Proteomic analysis of Exosomes derived from the Aqueous Humor of Myopia Patients
Tsai, C.-Y., Chen, C.-T., Lin, C.-H., Liao, C.-C., Hua, K., Hsu, C.-H., & Chen, C. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51735 · Cited by 31
“Recently, exosomes have been indicated to pass through the blood-brain barrier [40], it would be possible for the AH exosomes carrying HPX or TTR to also pass through the blood-retinal barrier.”
BackgroundExosomes: Small EVs with Large Immunomodulatory Effect in Glioblastoma
Benecke, L., Coray, M., Umbricht, S., Chiang, D. M., Figueiró, F., & Müller, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073600 · Cited by 33
“However, there was a high variance concerning rates and vesicular‐mediated mechanisms[98].”
BackgroundExosomes in Epilepsy of Tuberous Sclerosis Complex: Carriers of Pro-Inflammatory MicroRNAs
Cukovic, D., Bagla, S., Ukasik, D., Stemmer, P. M., Jena, B. P., Naik, A. R., Sood, S., Asano, E., Luat, A. F., Chugani, D. C., et al. (2021) · Non-Coding RNA · doi:10.3390/ncrna7030040 · Cited by 35
“Importantly, EV transport across the BBB appears to be further facilitated by neuroinflammation [44].”
BackgroundRizwan, M. N., Ma, Y., Nenkov, M., Jin, L., Schröder, D. C., Westermann, M., Gaßler, N., & Chen, Y. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23378 · Cited by 31
“Additionally, exosomes carrying cargoes like RNA, DNA, and miRNA are well‐tolerated, have low immunogenicity and a longer circulating half‐life in human body, and can cross the biological barrier, for example, the blood‐brain barrier.(92,112,113) Exosomes can be engineered to deliver anticancer drugs by different appr…”
BackgroundRohden, F., Teixeira, L. V., Bernardi, L. P., Ferreira, P. C. L., Colombo, M., Teixeira, G. R., de Oliveira, F. D. S., Lima, E. O. C., Guma, F. T. C. R., & Souza, D. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312860 · Cited by 33
“In previous experimental studies, EVs systemically administered after ischemic stroke increased angiogenesis and neurogenesis and attenuated neuroinflammation evoked by focal brain injury [34,38].”
BackgroundSingh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03475-z · Cited by 28
“As the sEVs’ composition bears the molecular signature of the secreting cell and bears an intrinsic property of transversing the blood–brain barrier (BBB) in both directions [40, 41], they are a target of constant research in neurodegenerative disease.”
BackgroundThe potential of exosomes as a new therapeutic strategy for glioblastoma
Silva, L. C., Branco, F., Cunha, J., Vitorino, C., Gomes, C. M. F., Carrascal, M. A., Falcão, A. C., Neves, B. M., & Cruz, M. T. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114460 · Cited by 30
Mediratta, K., Diab, M. D., Han, P., Hu, H., & Wang, L. (2025) · Nanomaterials · doi:10.3390/nano15181418 · Cited by 34
Vujić, T., Schvartz, D., Furlani, I. L., Meister, I., González‐Ruiz, V., Rudaz, S. L., & Sanchez, J. (2022) · Cells · doi:10.3390/cells11233926 · Cited by 29
“Their study on cultured cells exposed to oxidative stress showed an increased MMP-1 but reduced MMP-2 [29], contributing to a perturbed ECM homeostasis, and, thus, a possible BBB alteration.”
BackgroundInfluentialSmall Extracellular Vesicles’ miRNAs: Biomarkers and Therapeutics for Neurodegenerative Diseases
Lim, W. Q., Michelle Luk, K. H., Lee, K. Y., Nurul, N., Loh, S. J., Yeow, Z. X., Wong, Q. X., Daniel Looi, Q. H., Chong, P. P., How, C. W., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041216 · Cited by 25
Togre, N. S., Mekala, N. K., Bhoj, P. S., Mogadala, N., Winfield, M., Trivedi, J., Grove, D., Kotnala, S., Rom, S., Sriram, U., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03230-4 · Cited by 32
“EVs can cross BBB, carry exchange between the CNS and blood, and regulate neuroinflammation [96–98].”
BackgroundExtracellular vesicles as drug and gene delivery vehicles in central nervous system diseases
Shi, X., He, W., Gupta, A. B., To, K., Clark, L., Mirle, N., Wynn, T., Wang, D., Ganesh, A., Zeng, H. M., et al. (2025) · Biomaterials Science · doi:10.1039/d4bm01394h · Cited by 33
Horn, M. D., & MacLean, A. G. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695899 · Cited by 30
“In a study of EVs derived from seven human and three murine cell lines, Banks et al. (2020) found that all the EVs tested were capable of crossing the blood-brain barrier (BBB) of mice.”
BackgroundZarà, M., Campodonico, J., Cosentino, N., Biondi, M. L., Amadio, P., Milanesi, G., Assanelli, E. M., Cerri, S., Biggiogera, M., Sandrini, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158065 · Cited by 30
“Conversely to the higher level of circulating ceruloplasmin found in myocardial infarction patients, exosomes isolated from STEMI displayed a reduced level of ceruloplasmin, suggesting that exosome protein expression does not necessarily reflect circulating free-form levels of this positive acute-phase protein [20,39].”
BackgroundExtracellular Vesicles: A Novel Tool in Nanomedicine and Cancer Treatment
Stavrou, A., & Ortiz, A. (2022) · Cancers · doi:10.3390/cancers14184450 · Cited by 29
“One very important aspect of EVs that could solve a major problem in brain cancer treatments, is that they are able to pass through many physiological barriers within the body, including the blood–brain barrier (BBB) [58].”
BackgroundInfluentialExtracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment
Yan, B., & Liang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415758 · Cited by 29
“Compared with other drug delivery carriers, such as liposomes, viral vectors, and nanoparticles, EVs have a more complex membrane composition that assists the vesicles in traveling across the tight junction barriers to achieve selective cellular uptake [87,88].”
BackgroundMenjivar, N. G., Oropallo, J., Gebremedhn, S., Souza, L. A., Gad, A. Y., Puttlitz, C. M., & Tesfaye, D. (2024) · Biological Procedures Online · doi:10.1186/s12575-024-00241-6 · Cited by 29
“Fortunately, EVs effectively traverse this restriction via the bidirectional BBB transendothelial transport, both from the blood into the brain and from the brain into the blood [189].”
BackgroundAdvances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
Yan, D., Li, W., Liu, Q., & Yang, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914618 · Cited by 29
Proteomic Profiling of Aqueous Humor Exosomes from Age-related Macular Degeneration Patients
Tsai, C., Chen, C.-T., Wu, H.-H., Liao, C., Hua, K., Hsu, C.-H., & Chen, C. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.73489 · Cited by 27
“Recently, increasing evidence suggested exosome can cross biological barriers such as the blood- brain barrier (BBB) [39].”
BackgroundMechanisms and Biomarker Potential of Extracellular Vesicles in Stroke
Ollen‐Bittle, N., Roseborough, A. D., Wang, W., Wu, J.-L. D., & Whitehead, S. N. (2022) · Biology · doi:10.3390/biology11081231 · Cited by 33
“However, it is the ability of EVs to penetrate the blood-brain barrier (BBB) that has attracted the most recent attention, as they can be collected peripherally but used as a window into neuroinflammatory and neurodegenerative changes within the CNS [45].”
BackgroundBertolino, G. M., Maumus, M., Jørgensen, C., & Noël, D. (2022) · Biomedicines · doi:10.3390/biomedicines10092281 · Cited by 30
“Due to their small size, they can be easily biodistributed and can cross the blood–brain barrier [11].”
BackgroundPounders, J., Hill, E. J., Hooper, D., Zhang, X., Biesiada, J., Kuhnell, D., Greenland, H. L., Esfandiari, L., Timmerman, E., Foster, F., et al. (2022) · Medicine · doi:10.1097/md.0000000000030854 · Cited by 26
“[13,14] We sought to examine whether SEV miRNA profiles within neuron specific SEVs isolated from plasma differed among FTD, AD, and healthy aging controls.”
Bauman, M. M. J., Bouchal, S. M., Monie, D. D., Aibaidula, A., Singh, R., & Parney, I. F. (2022) · Neurosurgical FOCUS · doi:10.3171/2022.9.focus22430 · Cited by 26
High-mobility group box 1 (HMGB1) crosses the BBB bidirectionally
Banks, W. A., Hansen, K. M., Erickson, M. A., & Crews, F. T. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.018 · Cited by 30
Self-citationJackson, H. K., Mitoko, C. A., Linke, F., Macarthur, D., Kerr, I. D., & Coyle, B. (2023) · Cancers · doi:10.3390/cancers15092601 · Cited by 31
“The most investigated are small EVs (sEVs or exosomes), which are nanometer-sized vesicles secreted by all cell types and able to cross the blood–brain barrier (BBB) [4].”
BackgroundSaroj, S., Poornima, U. S., Patil, S., Paul, D., Saha, S., Ali, A., Pal, S., Lochab, B., & Rakshit, T. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c01108 · Cited by 30
Post-COVID-19 Parkinsonism and Parkinson’s Disease Pathogenesis: The Exosomal Cargo Hypothesis
Mysiris, D. S., Vavougios, G. D., Karamichali, E., Papoutsopoulou, S., Stavrou, V. T., Papayianni, E., Boutlas, S., Mavridis, T., Foka, P., Zarogiannis, S. G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179739 · Cited by 25
“Considering that exosomes can cross the BBB and act as fingerprints of their cellular originators, they could be used as CNS biomarkers that can be isolated and recovered from the periphery, with minimally invasive techniques [234].”
BackgroundExtracellular vesicles as contributors in the pathogenesis of multiple sclerosis
Zamboni, S., D’Ambrosio, A., & Margutti, P. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104554 · Cited by 27
Fallahi, S., Zangbar, H. S., Farajdokht, F., Rahbarghazi, R., Mohaddes, G., & Ghiasi, R. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14752 · Cited by 28
“9,10 13 Various experimental studies have shown the amazing effects of exosome therapy in attenuating different neurological disease signs.”
BackgroundGlial Cell Dynamics in Neuroinflammation: Mechanisms, Interactions, and Therapeutic Implications
García‐Domínguez, M. (2026) · Biomedicines · doi:10.3390/biomedicines14010115 · Cited by 36
“Reciprocal interactions between microglia and astrocytes play a central role in shaping the neuroinflammatory cascade.”
Chen, F., Yu, X., Shi, K., Zhang, Z., Xie, Z., Wu, H., Ma, Y., Zhou, Y. C., Chen, C. Y., Yang, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113685 · Cited by 27
Fan, L., Ma, X., Liu, B., Yang, Y., Yang, Y., Ren, T., & Li, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301865 · Cited by 26
WADHWA, K., Chauhan, P., Kumar, S., Pahwa, R., Verma, R., Goyal, R., Singh, G., Sharma, A., RAO, N., & Kaushik, D. K. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.047278 · Cited by 25
Exosomes: the next-generation therapeutic platform for ischemic stroke
Yin, W., Ma, H., Qu, Y., Ren, J., Sun, Y., Guo, Z., & Yang, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02051 · Cited by 29
Placental Extracellular Vesicles Can Be Loaded with Plasmid DNA
Kang, M., Hisey, C. L., Tsai, B., Nursalim, Y. N. S., Blenkiron, C., & Chamley, L. W. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00533 · Cited by 24
Rodríguez, C. I., Porcello, A., Chemali, M., Raffoul, W., Marques, C., Scaletta, C., Lourenço, K., Abdel-Sayed, P., Applegate, L. A., Vatter, F. A. P., et al. (2024) · Cosmetics · doi:10.3390/cosmetics11050154 · Cited by 28
“Notable lipid component examples include cholesterol, ceramides, sphingomyelin, phosphatidylinosol, phosphatidylserine, phosphatidylcholine, phosphatidyleth-anolamine, and gangliosides [21].”
Extracellular Vesicles: Diagnostic and Therapeutic Applications in Cancer
Bella, M. A. D., & Taverna, S. (2024) · Biology · doi:10.3390/biology13090716 · Cited by 33
“Moreover, sEVs have the ability to cross physiological barriers, such as the blood–brain-barrier (BBB), and accumulate at pathological sites [27–29].”
Advanced nanoparticle engineering for precision therapeutics of brain diseases
Ismail, M., Liu, J., Wang, N., Zhang, D., Qin, C., Shi, B., & Zheng, M. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123138 · Cited by 30
Harnessing the Potential of Exosomes in Therapeutic Interventions for Brain Disorders
Bai, L., Yu, L., Ran, M., Zhong, X., Sun, M., Xu, M., Wang, Y., Yan, X., Lee, R. J., Tang, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062491 · Cited by 28
Toxicological Profile of Umbilical Cord Blood-Derived Small Extracellular Vesicles
Rodrigues, S. C., Cardoso, R. M. S., Gomes, C. F., Duarte, F. V., Freire, P. C., das Neves, R. P., & Simões‐Correia, J. (2021) · Membranes · doi:10.3390/membranes11090647 · Cited by 22
Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination
Komi, D. E. A., Shafaghat, F., Alipoor, S. D., Kazemi, T., Atiakshin, D., Pyatilova, P., & Maurer, M. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09033-6 · Cited by 27
“…of penetrating cells and tissues and crossing barriers like blood brain barrier (BBB), the idea of their application in tumor progression control comes under the spotlight [182–185] flow cytometry, and proteomic analysis are widely used to confirm their effective isolation and content [186].”
Odehnalová, N., Šandriková, V., Hromádka, R., Skaličková, M., Dytrych, P., Hoskovec, D., Kejík, Z., Hajduch, J., Vellieux, F. M. D., Vašáková, M., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1539714 · Cited by 31
“The ability of exosomes to cross the blood–brain barrier (BBB) provides the opportunity for their use in the treatment of NDs (45, 170).”
Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer
Zhang, X., Artz, N., Steindler, D. A., Hingtgen, S., & Satterlee, A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189300 · Cited by 27
Edwards, K. A., Greer, K., Leete, J. J., Lai, C., Devoto, C., Qu, B., Yarnell, A. M., Polejaeva, E., Dell, K. C., LoPresti, M. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97913-0 · Cited by 22
Piffoux, M., Volatron, J., Silva, A., & Gazeau, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111931 · Cited by 24
“reported that EVs detected in mice brains after systemic injection (∼1% of total dose [57]) were located at 58–92% in the parenchyma depending on cell type [69], indicating a very good ability to cross the BBB.”
BackgroundAnakor, E., Milla, V., Connolly, O., Martinat, C., Pradat, P., Dumonceaux, J., Duddy, W. J., & Duguez, S. (2022) · Cells · doi:10.3390/cells11050845 · Cited by 25
“investigating uptake of exosomes of different cell origins in the context of exosome–brain interactions revealed that all tested exosomes crossed the brain–blood barrier (BBB), albeit at differing rates and with even distribution throughout the brain including the olfactory bulb, cortex, and cerebellum [61].”
BackgroundSaari, H., Pusa, R., Marttila, H., Yliperttula, M. L., & Laitinen, S. (2023) · Journal of Chromatography A · doi:10.1016/j.chroma.2023.464293 · Cited by 22
Kim, M., Choi, H., Jang, D., Kim, H., Sub, Y., Gee, H. Y., & Choi, C. (2024) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szae027 · Cited by 24
“4,5 They are also considered safe partly because of their immune tolerance.”
BackgroundFarley, J. T., Eldahshoury, M. K., & de Marcos Lousa, C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.883841 · Cited by 23
Tumor-derived Exosomes and Antitumor Immunity
Whiteside, T. L. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400335 · Cited by 25
Self-citationNakamya, M. F., Sil, S., Buch, S. J., & Hakami, R. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.840364 · Cited by 24
“EVs can cross the blood-brain-barrier (BBB) easily, facilitating material exchange between the CNS and blood circulation (Banks et al., 2020).”
BackgroundBanks, W. A., Sharma, P., Hansen, K. M., Ludwig, N., & Whiteside, T. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012513 · Cited by 22
“The analysis was performed for the four tissues as well as the previously published data for brain, which were from the same animals [18] The first step in path analysis was to determine the correlations among all tissue pairs using Spearman correlations.”
BackgroundMethodResultInfluentialSelf-citationStrategies for the Management of Spike Protein-Related Pathology
Halma, M. T. J., Plothe, C., Marik, P. E., & Lawrie, T. A. (2023) · Microorganisms · doi:10.3390/microorganisms11051308 · Cited by 23
“Extracellular vesicles are capable of crossing the blood–brain barrier [23], and LNPs, as well as exosomes, will exchange more readily in small diameter vessels with low flow rates (i.”
BackgroundAstrocyte involvement in metabolic regulation and disease
Naveed, M., Smedlund, K., Zhou, Q.-G., Cai, W., & Hill, J. W. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.001 · Cited by 29
Pusic, K. M., Kraig, R. P., & Pusic, A. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255778 · Cited by 23
“2 mm thick [35], and inflammation is known to impact EV uptake [36, 37].”
BackgroundAldawsari, H. M., Badr-Eldin, S. M., Assiri, N. Y., Alhakamy, N. A., Privitera, A., Caraci, F., & Caruso, G. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2110996 · Cited by 22
“It is well-known that nanoparticles with a size smaller than 200 nm, representing the estimated limiting size for a nanoparticle to undergo endocytosis through a clathrin-mediated mechanism, are more efficient in crossing the BBB (Betzer et al., 2017); however, the lower ability to cross the BBB of nanoparticles chara…”
BackgroundInfluentialDardet, J. P., Serrano, N., Andras, I. E., & Toborek, M. J. (2022) · Frontiers in Drug Delivery · doi:10.3389/fddev.2022.855017 · Cited by 22
Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases
Haghighitalab, A., Dominici, M., Matin, M. M., Shekari, F., Warkiani, M. E., Lim, R., Ahmadiankia, N., Mirahmadi, M., Bahrami, A. R., & Bidkhori, H. R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1090416 · Cited by 23
Extracellular vesicles for developing targeted hearing loss therapy
Pan, X., Li, Y., Huang, P., Staecker, H., & He, M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.050 · Cited by 25
Metadata
- Authors
- Banks, W. A., Sharma, P., Bullock, K. M., Hansen, K. M., Ludwig, N., & Whiteside, T. L.
- Affiliations
- University of Washington (US)
- University of Pittsburgh (US)
- Corresponding author
- Banks, William A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-21
- Volume
- 21
- Issue
- 12
- Pages
- 4407
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352415
- OpenAlex
- W3036596408
- Cited by
- 561
- References
- 57
- Citations by year
- 2026: 99 · 2025: 102 · 2024: 132 · 2023: 90 · 2022: 81 · 2021: 54 · 2020: 2
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health (1RO1 AG046619)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- extracellular vesicles, exosomes, blood-brain barrier, BBB crossing, brain pharmacokinetics, lipopolysaccharide, inflammation, mannose 6-phosphate receptor, CD46, integrins, ICAM-1, vesicular transporters
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Cell Line, Humans, Inflammation, Male, Cell Line, Tumor, Mice, Exosomes, Transcytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.